Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Argenx Se (ARGX – Research Report). The associated price target is $761.00.
Yaron Werber has given his Buy rating due to a combination of factors including Argenx Se’s strong financial performance and promising future prospects. The company reported impressive revenue growth for Vyvgart, with a significant increase in both quarterly and yearly figures. This growth is largely driven by the successful launch in the CIDP market and continued momentum in the MG market, with expectations for further expansion into seronegative and ocular MG.
Additionally, Argenx Se’s pipeline is advancing rapidly, with several promising studies underway that could further enhance market opportunities. The company’s strategic focus on expanding its prescriber and patient base, coupled with the potential for new indications and pipeline developments, supports the positive outlook. Furthermore, the upward revision of earnings estimates and the increase in the price target reflect confidence in the company’s profitability and growth trajectory.